Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes

Area of Science:

• Biotechnology
• Immunology
• Nanomedicine

Background:

• Exosomes are crucial for intercellular communication and offer unique advantages for therapeutic development.
• While successful in drug delivery, exosomes' potential in immunotherapy is largely unexplored.
• Targeted delivery and immune modulation are key challenges in cancer immunotherapy.

Purpose of the Study:

• To engineer exosomes with specific targeting and immunomodulatory capabilities for cancer therapy.
• To develop a versatile platform for exosome-based immunotherapeutics.
• To evaluate the efficacy of engineered exosomes against triple-negative breast cancer (TNBC).

Main Methods:

• Genetically engineered exosomes (GEMINI-Exos) were created by fusing targeting antibodies (anti-CD3, anti-EGFR) and immune checkpoint modulators (PD-1, OX40L) to exosomal membrane proteins.
• Exosomes were derived from Expi293F cells.
• The anti-cancer efficacy of GEMINI-Exos was assessed in preclinical models of EGFR-positive TNBC.

Main Results:

• GEMINI-Exos successfully displayed antibodies and immunomodulatory proteins on their surface.
• Engineered exosomes effectively redirected and activated T-cells to target EGFR-positive TNBC cells.
• GEMINI-Exos demonstrated potent inhibition of established TNBC tumors in mice, eliciting robust anti-cancer immunity.

Conclusions:

• Genetically engineered exosomes (GEMINI-Exos) represent a promising new class of agents for cancer immunotherapy.
• This approach provides a general strategy for developing exosome-based immunotherapeutics with tailored functions.
• GEMINI-Exos show significant potential for treating triple-negative breast cancer and other malignancies.